At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
R21/Matrix-M1 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib Randomised, Controlled, Single-blind Study to Assess the Safety, Immunogenicity of the Malaria Vaccine Candidate R21 With Matrix-M1 Adjuvant in West African Adult Volunteers
In Brief
A Phase 2 clinical trial evaluating R21/Matrix-M1 and Saline for Malaria. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This is a study in which healthy adult volunteers will be given either an experimental Malaria vaccine or a saline control vaccine. Each volunteer will receive three vaccinations in total. Volunteers will be randomly allocated to one of two groups: Group 1 will receive a low dose of the Malaria vaccine on days 0, 28, and 56. Group 2 will receive a saline solution on days 0, 28, and 56.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesBurkina Faso
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedOct 2016
Primary CompletionFeb 2017
TodayJul 2026
First PostedOct 5, 2016
Enrollment StartAug 26, 2016
Primary CompletionFeb 15, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.7 years ago
Interventions
R21/Matrix-M1biological
Salineother